BCL-2 represents a new therapeutic target in oestrogen-positive breast cancer | Prof Geoff Lindeman at St. Gallen Breast Cancer Conference 2015

BCL-2 represents a new therapeutic target in oestrogen-positive breast cancer | Prof Geoff Lindeman at St. Gallen Breast Cancer Conference 2015

User Photo
EMJ

5 years
458 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) discusses the importance of the new therapeutic targets of BCL-2, BH3 mimetics, in oestrogen receptor-positive (ER+) breast cancer, including the challenges in the development process and use in clinical practice.

Preclinical models of ER+ breast cancer demonstrate that BH3 mimetics combined with tamoxifen improves the effectiveness of hormone therapy. Clinical studies of the BH3 mimetic, ABT-199, are beginning in ER+ breast cancer.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay